CN107029023A - A kind of Chinese medicine composition and application - Google Patents
A kind of Chinese medicine composition and application Download PDFInfo
- Publication number
- CN107029023A CN107029023A CN201710282607.7A CN201710282607A CN107029023A CN 107029023 A CN107029023 A CN 107029023A CN 201710282607 A CN201710282607 A CN 201710282607A CN 107029023 A CN107029023 A CN 107029023A
- Authority
- CN
- China
- Prior art keywords
- group
- ginsenoside
- polygalic acid
- chinese medicine
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 39
- 239000003814 drug Substances 0.000 title claims abstract description 36
- VZRKWGPIZJDNHC-LUNVCWBOSA-N Polygalic acid Polymers CC1(C)CC[C@@]2(CCC3=C(CC[C@@H]4[C@@]5(C)C[C@H](O)[C@H](O)[C@](C)([C@@H]5CC[C@@]34C)C(O)=O)[C@@H]2C1)C(O)=O VZRKWGPIZJDNHC-LUNVCWBOSA-N 0.000 claims abstract description 68
- VZRKWGPIZJDNHC-UHFFFAOYSA-N Polygalic acid Natural products CC1(C)CCC2(CCC3=C(CCC4C5(C)CC(O)C(O)C(C)(C5CCC34C)C(O)=O)C2C1)C(O)=O VZRKWGPIZJDNHC-UHFFFAOYSA-N 0.000 claims abstract description 58
- 229930182494 ginsenoside Natural products 0.000 claims abstract description 58
- 229940089161 ginsenoside Drugs 0.000 claims abstract description 55
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 40
- 102000004169 proteins and genes Human genes 0.000 claims description 11
- 108090000623 proteins and genes Proteins 0.000 claims description 11
- 229960004373 acetylcholine Drugs 0.000 claims description 9
- 235000013402 health food Nutrition 0.000 claims description 9
- 101000741929 Caenorhabditis elegans Serine/threonine-protein phosphatase 2A catalytic subunit Proteins 0.000 claims description 8
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 claims description 8
- 230000006872 improvement Effects 0.000 claims description 7
- 230000009467 reduction Effects 0.000 claims description 7
- 102000004190 Enzymes Human genes 0.000 claims description 5
- 108090000790 Enzymes Proteins 0.000 claims description 5
- 101150090422 gsk-3 gene Proteins 0.000 claims description 3
- 241000700159 Rattus Species 0.000 abstract description 43
- 230000000694 effects Effects 0.000 abstract description 23
- 230000000857 drug effect Effects 0.000 abstract description 3
- 241000208340 Araliaceae Species 0.000 description 42
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 41
- 235000003140 Panax quinquefolius Nutrition 0.000 description 41
- 235000008434 ginseng Nutrition 0.000 description 41
- 241000208966 Polygala Species 0.000 description 39
- 238000002474 experimental method Methods 0.000 description 12
- 210000004556 brain Anatomy 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 230000015654 memory Effects 0.000 description 7
- 102000001267 GSK3 Human genes 0.000 description 6
- 108060006662 GSK3 Proteins 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 210000001320 hippocampus Anatomy 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- NFVJNJQRWPQVOA-UHFFFAOYSA-N n-[2-chloro-5-(trifluoromethyl)phenyl]-2-[3-(4-ethyl-5-ethylsulfanyl-1,2,4-triazol-3-yl)piperidin-1-yl]acetamide Chemical compound CCN1C(SCC)=NN=C1C1CN(CC(=O)NC=2C(=CC=C(C=2)C(F)(F)F)Cl)CCC1 NFVJNJQRWPQVOA-UHFFFAOYSA-N 0.000 description 5
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 4
- 230000006399 behavior Effects 0.000 description 4
- 210000005013 brain tissue Anatomy 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 229930182470 glycoside Natural products 0.000 description 4
- 150000002338 glycosides Chemical class 0.000 description 4
- 230000000971 hippocampal effect Effects 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 4
- 229930182490 saponin Natural products 0.000 description 4
- 150000007949 saponins Chemical class 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000000344 soap Substances 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000009189 diving Effects 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 230000009191 jumping Effects 0.000 description 3
- 230000013016 learning Effects 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 230000003285 pharmacodynamic effect Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000009182 swimming Effects 0.000 description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 238000012347 Morris Water Maze Methods 0.000 description 2
- 108090000244 Rat Proteins Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000007131 anti Alzheimer effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000000544 cholinesterase inhibitor Substances 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000005056 memory consolidation Effects 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- WZUVPPKBWHMQCE-XJKSGUPXSA-N (+)-haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 description 1
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 1
- 102100027831 14-3-3 protein theta Human genes 0.000 description 1
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- 102000012440 Acetylcholinesterase Human genes 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Natural products C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010059013 Nocturnal emission Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- -1 acetylcholine ester Chemical class 0.000 description 1
- 229940022698 acetylcholinesterase Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000002329 esterase inhibitor Substances 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000007087 memory ability Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000000879 optical micrograph Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000006919 peptide aggregation Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/69—Polygalaceae (Milkwort family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Steroid Compounds (AREA)
Abstract
The invention provides a kind of Chinese medicine composition, including polygalic acid and ginsenoside；The mass ratio of the polygalic acid and ginsenoside is less than or equal to 1.Compared with prior art, the present invention is by the way that two kinds of active components of polygalic acid and ginsenoside are shared, the behaviouristics obstacle of Alzheimer's Disease Rats is significantly improved, there is clearly treatment Alzheimer disease effect, and drug effect is substantially better than alone any of which.
Description
Technical field
The invention belongs to technical field of traditional Chinese medicines, more particularly to a kind of Chinese medicine composition and application.
Background technology
Alzheimer disease (Alzheimer ' s Disease, AD) is that a kind of reason is not clear based on cognitive decrease
Want the nervous system degenerative disease of clinical manifestation, be mainly shown as progressive disturbance of intelligence, failure of memory, with personality and
Feeling changes.Increasingly serious with China human mortality aging, AD has increasingly becomed a serious social concern.Therefore,
Various approach are found to go to realize that all very necessary also tool of the research work for treating and alleviating AD is of great significance.
Current AD medicine is mainly Western medicine, and traditional treatment AD medicine is mainly acetylcholinesteraseinhibitors inhibitors,
Slow down the degraded of cortical centre nerve release acetylcholine by acetylcholine esterase inhibition, so as to increase acetylcholine
Concentration, improves the cognitive function and behavior disorder of patient AD, delays the generation of disease, but clinical therapeutic efficacy is not good, and makes it
Clinical practice is limited by larger.And the problem of acetylcholinesteraseinhibitors inhibitors only address only " mark ", does not change
" sheet ", these medicines are only capable of within short-term (6~12 months) improving the symptom (such as cognitive ability) of AD patient, to the day of patient
Often life and neuropsychic symptom (such as disturbance of emotion, anxiety, mental aberration) have not improved significantly.
The content of the invention
In view of this, the technical problem to be solved in the present invention is to provide a kind of Chinese medicine for having and treating Alzheimer disease
Composition and application.
The invention provides a kind of Chinese medicine composition, including polygalic acid and ginsenoside；The polygalic acid and ginseng
The mass ratio of saponin(e is less than or equal to 1.
It is preferred that, the mass ratio of the polygalic acid and ginsenoside is 1：(1~2).
It is preferred that, the mass ratio of the polygalic acid and ginsenoside is 1：1.
It is preferred that, the mass ratio of the polygalic acid and ginsenoside is 1：2.
Preparing treatment present invention also offers above-mentioned Chinese medicine composition and/or improving medicine or the guarantor of Alzheimer disease
Application in health food.
It is preferred that, the treatment and/or improvement Alzheimer disease are reduction intracerebral enzyme acetylcholine content.
It is preferred that, the treatment and/or improvement Alzheimer disease are reduction intracerebral p-tau protein levels, the albumen of GSK 3
Level and aβ protein level, increase PP2A protein levels.
Present invention also offers a kind of medicine, including above-mentioned Chinese medicine composition.
Present invention also offers a kind of health food, including above-mentioned Chinese medicine composition.
The invention provides a kind of Chinese medicine composition, including polygalic acid and ginsenoside；The polygalic acid and ginseng
The mass ratio of saponin(e is less than or equal to 1.Compared with prior art, the present invention is by by polygalic acid and the effective portion of two kinds of ginsenoside
Position is shared, and significantly improves the behaviouristics obstacle of Alzheimer's Disease Rats, there is clearly treatment Alzheimer disease effect, and
Drug effect is substantially better than alone any of which.
Brief description of the drawings
Fig. 1 is that the positioning of each group rat in the embodiment of the present invention 1 is cruised infrared thermal map；
Fig. 2 be the embodiment of the present invention 1 in each group rat the infrared thermal map of space exploration；
Fig. 3 is each group Rat hippocampus HE colored graphs in the embodiment of the present invention 2；
Fig. 4 is that each group rat protein content table in the embodiment of the present invention 3 reaches figure.
Embodiment
Below in conjunction with the embodiment of the present invention, the technical scheme in the embodiment of the present invention is clearly and completely described,
Obviously, described embodiment is only a part of embodiment of the invention, rather than whole embodiments.Based in the present invention
Embodiment, the every other embodiment that those of ordinary skill in the art are obtained under the premise of creative work is not made, all
Belong to the scope of protection of the invention.
The invention provides a kind of Chinese medicine composition, including polygalic acid and ginsenoside；The polygalic acid and ginseng
The mass ratio of saponin(e is less than or equal to 1.
The traditional Chinese medical science thinks " the main intelligence of kidney, kidney deficiency then its not enough forgetful foreword of intelligence ", kidney deficiency marrow is empty, brain mansion lose support, refreshing machine operation is lost
It is often Alzheimer disease (AD) main pathogenesis.
Ginseng, araliaceae ginseng plant, the rare Chinese medicine of China is widely used in China, Europe, Southeast Asia, America.
《Sheng Nong's herbal classic》Record " ginseng, sweet to be slightly cold, main tonifying five zang organs (liver, the heart, spleen, lung, kidney), soothe the nerves, determine soul, stop palpitate with fear,
Remove pathogenic factor, improving eyesight, happy intelligence development ".
The ground such as polygala, Polygalaceae polygala, main product and China northeast, North China, northwest and Central China and Sichuan.《God
Agriculture book on Chinese herbal medicine warp》" polygala, bitter pungent-warm, tranquilize the mind and promote the intelligence, Xie Yu control palpitation with fear, forgetful, nocturnal emission, insomnia, cough ant phlegm, ulcer for record
Sore swells ".
The present invention significantly improves Alzheimer disease by the way that two kinds of active components of polygalic acid and ginsenoside are shared
The behaviouristics obstacle of rat, there is clearly treatment Alzheimer disease effect, and drug effect is substantially better than alone any of which；
Through experimental verification of the present invention, it can reduce intracerebral enzyme acetylcholine content or reduction intracerebral p-tau protein levels, the albumen of GSK 3
Level and aβ protein level, increase PP2A protein levels.
According to the present invention, the mass ratio of the polygalic acid and ginsenoside is preferably 1：(1~10), more preferably 1：(1
~5), it is further preferably 1：(1~2), most preferably 1：1 or 1：2.
Preparing treatment present invention also offers above-mentioned Chinese medicine composition and/or improving medicine or the guarantor of Alzheimer disease
Application in health food.
In the embodiment that the present invention is provided, treatment and/or improvement Alzheimer disease reduction intracerebral enzyme acetylcholine contain
Amount or reduction intracerebral p-tau protein levels, GSK3 protein levels and aβ protein level, increase PP2A protein levels.
Present invention also offers a kind of medicine, including above-mentioned Chinese medicine composition；Preferably, the medicine also includes pharmacy
Upper acceptable auxiliary material；Preferably, the formulation of the medicine be paste, it is granule, pill, powder, tablet, capsule, oral
Agent or syrup.But the formulation of medicine is not limited to this, those skilled in the art think feasible formulation the present invention's
Within protection domain.
Present invention also offers a kind of health food, including the Chinese medicine composition that the present invention is provided.
Preferably, the health food also includes acceptable food additives on food.
Preferably, the formulation of the health food be granule, capsule, syrup, tablet, pulvis, soft sweets, emulsion or
Oral liquid.But the formulation of health food is not limited to this, those skilled in the art think feasible formulation the present invention's
Within protection domain.
A kind of Chinese medicine composition provided with reference to embodiments the present invention to further illustrate the present invention and application
It is described in detail.
Reagent used is commercially available in following examples.
The polygalic acid of embodiment 1 and Panaxsaponin composition improve the pharmacodynamic study of AD behaviouristics obstacles
1.1 experimental method
1.1.1 experiment packet and administration
Wistar rats, male, 180~220g of body weight, purchased from Bethune medical college of Jilin University animal experimental center, is permitted
Can the number of card：SCXK (Ji) 2015-0007.
After adaptability is raised one week, 7 groups are randomly divided into, i.e.,：Blank group, model group, polygalic acid group, ginsenoside group,
Polygalic acid and ginsenoside combination 1:1 group, polygalic acid and ginsenoside combine 2:1 group, polygalic acid and ginsenoside group
Close 1:2 groups.
In addition to blank group, D- galactolipins 60mg/kg and gavage AlCl is injected intraperitoneally in remaining each group3200mg/kg modelings,
1 time a day, continuous 60d.30d starts blank group and model group and gives distilled water, polygalic acid and ginsenoside by 10mL/kg
Combination partner An not 300mg polygalic acid+300mg ginsenosides, 400mg polygalic acid+200mg ginsenosides, 200mg polygalas
Saponin(e+400mg ginsenosides/kg gives composition, and polygalic acid group 600mg/kg gives polygalic acid, and ginsenoside group is pressed
600mg/kg gavages give ginsenoside, once a day, continuous 30d.
Polygalic acid and ginsenoside are total saposins, and mass fraction respectively reaches more than 50%.
1.1.2 diving tower Behaviors survey
After last dose, rat Jumping test is carried out.Rat is placed on SDT-8 Jumping test video analysis first during experiment
5min is adapted on system copper grid, 36V electric currents are then passed to, copper grid is contacted simultaneously using rat biped to get an electric shock, is considered as wrong reaction,
The errors number of rat is recorded as school grade, 5min is trained.After 24h, tested again again, rat is placed in plastics
5min is adapted on diving tower, 36V electric currents are then passed to, what record was jumped off in the incubation period and 5min of platform for the 1st time jumps off platform
Errors number, if rat is rested on more than 5min on platform, its incubation period is in terms of 300s.
1.1.3 Morris Behaviors surveys
It is divided into compatibility test, positioning cruise experiment and space search experiment.
Compatibility test：The previous day is tested, rat is faced into pool wall is put into dehumidify after water went swimming 120s and put back in cage, enter
Row is adapted to.
Orientation navigation experiment：The a certain amount of water of injection in labyrinth (diameter 120cm, high 50cm), water temperature is controlled 24 ± 2
℃.4 place of entry are chosen, and labyrinth is divided into 4 quadrants.Transparent plastic platform is placed (directly in any quadrant center wherein
Footpath 10cm), 2cm in underwater, and keep its position constant in experimentation.Skimmed milk power is added in water prevents rat from seeing
To platform.Rat is faced during pool wall is sequentially put into water from all quadrants place of entry respectively, it is recorded and finds and climb up in 120s
The time of platform, as escape latency, climb up allows rat to stop 20s on platform after platform, is carried out after the 60s of interval next
Secondary test.If rat fails to find platform in 120s, drawn upper mounting plate and stop 20s, recording its incubation period is
120s.Experiment is carried out continuously 5 days.
Space exploration is tested：Orientation navigation experiment terminates after 24h, takes out platform, where original platform quadrant it is relative as
Rat is put into water by limit place of entry, quadrant distance where gathering the number of times that effective coverage is passed through in its 120s and original platform/total
The experiment parameters such as distance.
1.1.4 in body Acetylcholinesterasein measure
(1) processing of sample
After Behaviors survey terminates, anesthetized animal takes blood, and ice platform quickly takes brain, is put into glass dish, and glass dish is added
A small amount of ice-cold physiological saline rinsing, the moisture and blood on cerebral tissue surface are sucked with clean filter paper.Precise weighing, is put into
In small beaker.A small amount of ice-cold physiological saline is added, tissue block is shredded as early as possible with eye scissors.The tissue shredded is poured into glass even
Starch in device, then the broken tissue block remained in beaker is rinsed with a little ice-cold normal saline, pour into ice is carried out in homogenizer together
Bath homogenate.Then the physiological saline of freezing is added, by brain weight and homogenate cumulative volume 1：10 ratio, dilution is mixed.
10% brain homogenate prepared is centrifuged into 15min with 3000rpm/min, takes supernatant to be measured.The blood of taking-up with 2500rpm/min from
Heart 10min, takes upper serum.Serum is pressed 1 with physiological saline during survey：9 dilutions.
(2) measure of brain tissue protein content
Using Coomassie brilliant blue kit measurement brain tissue protein content.
(3) measure of AchE vigor
With improvement Ellman colorimetric method for determining AchE vigor, the method for determining kit by acetylcholine esterase is determined.
If standard pipe group, not dosing determine pipe group, test-compound and determine pipe group (dosing group), every group is all provided with blank control pipe and measure
Pipe, big rat brain tissue homogenate's liquid and serum sample amount are the often μ L of pipe 30.Reaction system is mixed, 37 DEG C of accurate response 6min, then
Terminating reaction, is mixed and places 15min, and each pipe absorbance is determined in 412nm wavelength.
AchE vigor (U/mL)=(A determines pipe-A control tubes)/(A standard pipe-A blank tubes) × standard pipe concentration in serum
(1 μm of ol/mL)/protein content (mg/mL).
1.2 data statistical approach
Data processing is carried out using the statistical softwares of SPSS 10.0.Experimental result is with mean ± standard deviationRepresent,
Compare between Student ' s t-test groups.P<0.05 is that difference is statistically significant.
1.3 experimental result
1.3.1 the pharmacodynamic study of polygalic acid and Panaxsaponin composition to rat diving tower behaviouristics obstacle
Compared with blank group, the first errors number and 24h errors numbers of model group rats substantially increase, 24h mistakes
Shorter latencies；Compared with model group, polygalic acid and the ginsenoside first errors number of combination group rat and 24h errors numbers
Significantly reduce, 24h error latences extend, wherein polygala ginseng 1：1 group and polygala ginseng 1：2 groups, than alone polygalic acid or
Ginsenoside any one effect is obvious, polygala ginseng 2：1 group of effect is not so good as alone polygalic acid or ginsenoside, is shown in Table 1.
Table 1 to AD Rats With Memories obtain and memory consolidation obstacle influence (N=10)
Compared with blank group, #p<0.05；Compared with model group, * * p<0.01, * p<0.05.
1.3.2 polygalic acid and Panaxsaponin composition are ground to the pharmacodynamics of treated rats in Morris water maze performance behaviouristics obstacle
Study carefully
1.3.2.1 positioning cruise experiment
1.3.2.1.1 each group animal thermal infrared track
(Fig. 1, wherein a are blank group to the infrared thermal map of positioning cruise, and b is model group, and c is polygala ginseng 1:1 group, d is
Polygala ginseng 2:1 group, e is polygala ginseng 1:2 groups, f is polygalic acid group, and g is ginsenoside group) as can be seen that blank group is moved
Thing can find target position (third quadrant) soon, and model group animal is main in peripheral activity, and zone of action exists
All quadrants are distributed without significant difference, show that model group's learning and memory ability and Memory acquisition ability are impaired.Polygalic acid and
Ginsenoside combination group animal can find target region quickly, and scope of activities is compared compared with model group and is reduced significantly, wherein
Polygala ginseng 1：1 group and polygala ginseng 1：It is 2 groups, more obvious than alone polygalic acid or any effect of ginsenoside, polygala people
Ginseng 2：1 group of effect is good not as alone polygalic acid or ginsenoside improvement AD learning and memory in rats ability effects.
1.3.2.1.2 AD rat escape latencies
Compared with blank group, model group rats increase for 5 days in intrinsic incubation, show model group's learning and memory behavior
Ability is substantially damaged.Compared with model group, polygalic acid and ginsenoside combination group rat shorten for 5 days in intrinsic incubation, with
Change in first 3 days is obvious, wherein polygala ginseng 1：1 group and polygala ginseng 1：2 groups, more any than alone polygalic acid or ginsenoside one
Plant effect substantially, polygala ginseng 2：1 group of effect is not so good as alone polygalic acid or ginsenoside, is shown in Table 2.
The continuous 5 days escape latencies (s) of each group animal of table 2
| 1st day | 2nd day | 3rd day | 4th day | 5th day | |
| Blank group | 36.56±7.79 | 17.91±1.55 | 15.56±3.18 | 11.67±5.09 | 10.41±8.10 |
| Model group | 51.04±3.44# | 36.54±3.29## | 29.53±7.35## | 25.36±7.57# | 22.78±7.48# |
| Polygala ginseng 1：1 group | 44.49±3.58* | 29.53±7.62* | 20.05±5.13* | 18.38±3.49# | 16.69±5.41 |
| Polygala ginseng 2：1 group | 49.04±4.07 | 34.04±3.95 | 27.03±5.15 | 23.36±7.57 | 19.78±7.48 |
| Polygala ginseng 1：2 groups | 42.13±2.98** | 27.33±3.12** | 19.15±2.93** | 16.82±5.91** | 15.99±6.21* |
| Polygalic acid group | 47.23±4.21* | 31.48±2.33* | 25.72±4.45* | 20.46±5.46* | 18.44±6.22 |
| Ginsenoside group | 48.32±5.47* | 33.15±3.46* | 28.41±8.82* | 22.56±6.78* | 17.86±2.74 |
Compared with blank group,##P<0.01；Compared with model group, * P<0.05, * * P<0.01.
1.3.2.2 space search is tested
1.3.2.2.1 each group animal thermal infrared track
(Fig. 2, wherein a are blank group to the infrared thermal map of space exploration, and b is model group, and c is polygala ginseng 1:1 group, d is
Polygala ginseng 2:1 group, e is polygala ginseng 1:2 groups, f is polygalic acid group, and g is ginsenoside group) as can be seen that blank group is big
The frequency that mouse third quadrant (primary image limit) where original platform occurs is more, and model group animal is main in peripheral activity, activity
Region is distributed without significant difference in all quadrants, and the above results show that model group rats memory consolidation ability is damaged.With model group ratio
Compared with wherein polygala ginseng 1：1 group and polygala ginseng 1：It is 2 groups, more obvious than alone polygalic acid or any effect of ginsenoside,
Polygala ginseng 2：To consolidate ability effect good not as alone polygalic acid or ginsenoside improve AD Rats With Memories for 1 group of effect.
1.3.2.1.2 each group animal space search regional movement situation
Compared with blank group, model group rats are in the run duration of effective coverage (third quadrant), move distance and entrance
The number of times of effective coverage is reduced, and the percentage into effective coverage is significantly reduced.Compared with model group, wherein polygala ginseng 1：
1 group and polygala ginseng 1：It is 2 groups, more obvious than alone polygalic acid or any effect of ginsenoside, into effective coverage pair
It run duration, increased apart from number of times, in the swimming time and swimming distance of third quadrant, increased, polygala people
Ginseng 2：1 group of effect is not so good as alone polygalic acid or ginsenoside, is shown in Table 3.
The each group animal space search experimental data of table 3
Compared with blank group,#P<0.05；Compared with model group, * * P<0.01, * P<0.05.
1.3.3 the influence of polygalic acid and Panaxsaponin composition to AD AcetylcholinesteraseIn In The Brains of Rat contents
Compared with blank group, the intracerebral acetylcholine ester enzyme level of model group rats substantially increases；Compared with model group, far
Will ginseng 1：1 group and polygala ginseng 1：It is 2 groups, more obvious than alone polygalic acid or any effect of ginsenoside, polygala ginseng
2：1 group of effect is not so good as alone polygalic acid or ginsenoside, is shown in Table 4.
The ginseng polygala compatibility of table 4 to AD AcetylcholinesteraseIn In The Brains of Rat influence (N=10)
| Group | AchE vigor (U/mg tissues) |
| Blank group | 0.079±0.033 |
| Model group | 0.199±0.023## |
| Polygala ginseng 1：1 group | 0.123±0.021* |
| Polygala ginseng 2：1 group | 0.153±0.202* |
| Polygala ginseng 1：2 groups | 0.119±0.123** |
| Polygalic acid group | 0.144±0.011* |
| Ginsenoside group | 0.157±0.031* |
Compared with blank group, ##P<0.01；Compared with model group, * * P<0.01, * P<0.05.
1.4 conclusion
Jumping test and Morris water maze laboratories subordinate act evaluate polygalic acid, Panaxsaponin composition and alone
The internal anti-AD effects of polygalic acid or ginsenoside, show Panaxsaponin composition can substantially increase AD Rats With Memories obtain,
Consolidate ability, improve cognitive disorder, reduce intracerebral acetylcholinesterase content, effect is better than alone polygalic acid or ginseng soap
Glycosides.
The polygalic acid of embodiment 2 and Panaxsaponin composition are to AD rat hippocampal histopathology Senile Mouses
2.1 experimental method
Rat breaks end, and takes brain, separation hippocampal tissue and cortex, hippocampal tissue immerses fixed in 4% paraformaldehyde, through de-
Water, waxdip, FFPE prepare paraffin section, then in turn through dimethylbenzene dewaxing, drop graded ethanol aquation, haematoxylin and she
Red colouring, liter gradient alcohol dehydration, dimethylbenzene are transparent, neutral gum mounting operation, prepare the Cardiac muscle sections of HE dyeing,
In the pathological change of optical microphotograph Microscopic observation hippocampal tissue.
2.2 experimental result
Each group rat cerebral tissue is taken, hippocampus position HE dyeing is carried out, it is as a result as follows：Blank group hippocampus and nerve under cortex
First complete, nucleus has no that purple is fine and close in denaturation, nucleus, and neural identical permutation is close.Model group hippocampus and god under cortex
It is denatured through member, cell caryoplasm is loose, polygala ginseng 1：1 group and polygala ginseng 1：2 groups, than alone polygalic acid or ginseng soap
Substantially, the neural loose neuronal degeneration degree of identical permutation is light compared with model group, and neural identical permutation is compared with model group for glycosides any one effect
Closely, neuronal degeneration quantity is less than polygalic acid group and ginsenoside group, polygala ginseng 2：1 group of effect is not so good as alone polygala soap
Glycosides or ginsenoside, it is each group Rat hippocampus HE colored graphs to see Fig. 3, Fig. 3, and wherein A is blank group, and B is model group, and C is
Polygalic acid：Ginsenoside 1:1 group, D is polygalic acid：Ginsenoside 2:1 group, E is polygalic acid：Ginsenoside 1:2 groups, F
For polygalic acid group, G is ginsenoside group.
The influence of the polygalic acid of embodiment 3 and Panaxsaponin composition to correlative protein expression in AD rat brains
3.1 experimental method
Using Western Blot to being respectively blank group, model group, polygalic acid group, ginsenoside group, polygala soap
The four kind albumen related to AD generations, development in glycosides and ginsenoside combination group, rat brain brain tissue：p-tau、GSK3、Aβ、
PP2A levels are expressed, using GAPDH as internal reference albumen, and gray analysis is carried out using image J image processing softwares.
3.2 experimental result
Compared with blank group, model group A β levels and the increase of p-tau, GSK3 level；Compared with model group, polygalic acid and
Panaxsaponin composition can substantially reduce by tri- kinds of protein levels of intracerebral p-tau, GSK3, A β, increase PP2A protein levels, improve AD
The cognitive disorder of rat, it is that each group rat protein content table reaches figure as a result to see Fig. 4, Fig. 4, and wherein A is blank group, and B is model group,
C is polygalic acid and ginsenoside 1:1 combination group, D is polygalic acid group, and E is ginsenoside group.
3.3 conclusion
Using Western Blot to four kinds of albumen related to AD generations, development in AD rat brains：p-tau、GSK3、
A β, PP2A levels are expressed, and are as a result shown, Panaxsaponin composition can substantially reduce the hatching eggs of intracerebral p-tau, GSK3, A β tri-
White level, increases PP2A protein levels.Its anti-AD mechanism may be relevant with influence Protein tau phosphorylation and A beta peptide aggregations.
Claims (9)
1. a kind of Chinese medicine composition, it is characterised in that including polygalic acid and ginsenoside；The polygalic acid and ginsenoside
Mass ratio be less than or equal to 1.
2. Chinese medicine composition according to claim 1, it is characterised in that the mass ratio of the polygalic acid and ginsenoside
For 1：(1~2).
3. Chinese medicine composition according to claim 1, it is characterised in that the mass ratio of the polygalic acid and ginsenoside
For 1：1.
4. Chinese medicine composition according to claim 1, it is characterised in that the mass ratio of the polygalic acid and ginsenoside
For 1：2.
5. the Chinese medicine composition described in Claims 1 to 4 any one is preparing treatment and/or is improving the medicine of Alzheimer disease
Application in thing or health food.
6. application according to claim 5, it is characterised in that the treatment and/or improvement Alzheimer disease are reduction
Intracerebral enzyme acetylcholine content.
7. application according to claim 5, it is characterised in that the treatment and/or improvement Alzheimer disease are reduction
Intracerebral p-tau protein levels, the protein levels of GSK 3 and aβ protein level, increase PP2A protein levels.
8. a kind of medicine, it is characterised in that including the Chinese medicine composition described in Claims 1 to 4 any one.
9. a kind of health food, it is characterised in that including the Chinese medicine composition described in Claims 1 to 4 any one.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710282607.7A CN107029023B (en) | 2017-04-26 | 2017-04-26 | Traditional Chinese medicine composition and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710282607.7A CN107029023B (en) | 2017-04-26 | 2017-04-26 | Traditional Chinese medicine composition and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107029023A true CN107029023A (en) | 2017-08-11 |
| CN107029023B CN107029023B (en) | 2020-12-29 |
Family
ID=59535231
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710282607.7A Expired - Fee Related CN107029023B (en) | 2017-04-26 | 2017-04-26 | Traditional Chinese medicine composition and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107029023B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107802636A (en) * | 2017-11-28 | 2018-03-16 | 新乡医学院 | A kind of pharmaceutical composition for treating Alzheimer's disease and its application |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101040863A (en) * | 2007-04-19 | 2007-09-26 | 暨南大学 | Chinese traditional medicine monocase compound for treating alzheimers disease |
| CN105535302A (en) * | 2014-10-30 | 2016-05-04 | 香港科技大学 | Pharmaceutical composition and preparation method thereof |
-
2017
- 2017-04-26 CN CN201710282607.7A patent/CN107029023B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101040863A (en) * | 2007-04-19 | 2007-09-26 | 暨南大学 | Chinese traditional medicine monocase compound for treating alzheimers disease |
| CN105535302A (en) * | 2014-10-30 | 2016-05-04 | 香港科技大学 | Pharmaceutical composition and preparation method thereof |
Non-Patent Citations (3)
| Title |
|---|
| 刘斌: "《中药成分体内代谢与分析研究》", 31 August 2011, 中国中医药出版社 * |
| 孙秀萍等: "人参总皂苷和远志总苷配伍对小鼠抗抑郁作用", 《中国比较医学杂志》 * |
| 彭成等: "《中药药理学》", 31 December 2014, 中国医药科技出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107802636A (en) * | 2017-11-28 | 2018-03-16 | 新乡医学院 | A kind of pharmaceutical composition for treating Alzheimer's disease and its application |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107029023B (en) | 2020-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ohnishi et al. | Loss of small peripheral sensory neurons in Fabry disease: histologic and morphometric evaluation of cutaneous nerves, spinal ganglia, and posterior columns | |
| CN102078460B (en) | Traditional Chinese medicine for preventing and treating Alzheimer disease and preparation method thereof | |
| Li et al. | Microglia TREM2: a potential role in the mechanism of action of electroacupuncture in an alzheimer’s disease animal model | |
| Huang et al. | The effect of early maternal separation combined with adolescent chronic unpredictable mild stress on behavior and synaptic plasticity in adult female rats | |
| Li et al. | Development and in vivo evaluation of hydroxy-α-sanshool intranasal liposomes as a potential remedial treatment for Alzheimer’s disease | |
| Li et al. | Schisandrin inhibits NLRP1 inflammasome-mediated neuronal pyroptosis in mouse models of Alzheimer’s disease | |
| CN107029023A (en) | A kind of Chinese medicine composition and application | |
| Al-Tawarah et al. | Rosmarinus officinalis and Mentha piperita oils supplementation enhances memory in a rat model of scopolamine-induced alzheimer’s disease-like condition | |
| Modupe et al. | Toxicological study of ethanol extract of Lavandula stoechas on Liver of Wistar rat | |
| Han et al. | Proteomics on the role of muscone in the “consciousness-restoring resuscitation” effect of musk on ischemic stroke | |
| Suciati et al. | Acetylcholinesterase inhibitory activity of extract and fractions from the root of Rauvolfia serpentina (L.) Bth. ex Kurz | |
| Rabie et al. | Improvement of advanced Parkinson’s disease manifestations with deep brain stimulation of the subthalamic nucleus: a single institution experience | |
| Bhupatiraju et al. | Influence of Murraya koenigii extract on diabetes induced rat brain aging | |
| Abdelghany et al. | Neuroprotective role of medicinal plant extracts evaluated in a scopolamine-induced rat model of Alzheimer's disease | |
| Liu et al. | Astragalus injection ameliorates lipopolysaccharide-induced cognitive decline via relieving acute neuroinflammation and BBB damage and upregulating the BDNF-CREB pathway in mice | |
| Strasser et al. | Transitive behavior in hippocampal-lesioned pigeons | |
| Jeong et al. | A 13-week repeated oral dose toxicity study of ChondroT in sprague-dawley rats | |
| Silva-Alves et al. | Essential oil of Croton zehntneri prevents conduction alterations produced by diabetes mellitus on vagus nerve | |
| Caffrey et al. | Cocaine-associated odor cue re-exposure increases blood oxygenation level dependent signal in memory and reward regions of the maternal rat brain | |
| Chvátal | Discovering the structure of nerve tissue: part 3: from Jan Evangelista Purkyně to Ludwig Mauthner | |
| Mate et al. | Enriched environment ameliorates propagation of tau pathology and improves cognition in rat model of tauopathy | |
| Kraft et al. | Trehalose reduces nerve injury induced nociception in mice but negatively affects alertness | |
| Cheng et al. | Effect of arborvitae seed on cognitive function and α7nAChR protein expression of hippocampus in model rats with Alzheimer’s Disease | |
| Kekeçoğlu et al. | Factors affecting quality of honey bee venom | |
| Shen et al. | Pre exposure to enriched environment alleviates brain injury after ischemia-reperfusion by inhibiting p38MAPK/STAT1 pathway |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20201229 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |